Gabrielle Sulzberger net worth and biography

Gabrielle Sulzberger Biography and Net Worth

Gabrielle Sulzberger currently serves as a partner at Fontis Partners, a private equity fund, where she has served since 2007. Prior to joining Fontis, Ms. Sulzberger served as chief financial officer of several public and private companies, including Gluecode Software, a venture-backed open source software company that was sold to IBM, and Crown Services, a California-based consolidation of commercial contractors.

Ms. Sulzberger currently serves as the chairman of the board of The Food Kitchen, as a member of the board of directors of MasterCard, Brixmor Property Group and as a board trustee of the Ford Foundation. Until August 2017, Ms. Sulzberger served as the chairperson of the board of directors of Whole Foods and as a member of the board of directors of Teva Pharmaceuticals and Stage Stores.

Ms. Sulzberger earned a B.A. from the Woodrow Wilson School of Princeton University, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School. She is a member of the Massachusetts Bar.

What is Gabrielle Sulzberger's net worth?: The estimated net worth of Gabrielle Sulzberger is at least $1.49 million as of June 17th, 2021. Ms. Sulzberger owns 35,354 shares of Cerevel Therapeutics stock worth more than $1,489,818 as of April 18th. This net worth estimate does not reflect any other investments that Ms. Sulzberger may own. Learn More about Gabrielle Sulzberger's net worth.
How do I contact Gabrielle Sulzberger?: The corporate mailing address for Ms. Sulzberger and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on Gabrielle Sulzberger's contact information.
Has Gabrielle Sulzberger been buying or selling shares of Cerevel Therapeutics?: Gabrielle Sulzberger has not been actively trading shares of Cerevel Therapeutics within the last three months. Most recently, on Thursday, June 17th, Gabrielle Sulzberger bought 21,084 shares of Cerevel Therapeutics stock. The stock was acquired at an average cost of $13.06 per share, with a total value of $275,357.04. Following the completion of the transaction, the director now directly owns 35,354 shares of the company's stock, valued at $461,723.24. Learn More on Gabrielle Sulzberger's trading history.
Who are Cerevel Therapeutics' active insiders?: Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.
Are insiders buying or selling shares of Cerevel Therapeutics?: In the last year, Cerevel Therapeutics insiders bought shares 4 times. They purchased a total of 6,462,597 shares worth more than $147,510,898.72. In the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 625,260 shares worth more than $21,054,440.60. The most recent insider tranaction occured on March, 4th when Director N Anthony Coles sold 50,000 shares worth more than $2,050,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.
Information on this page was last updated on 3/4/2024.

Gabrielle Sulzberger Insider Trading History at Cerevel Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/17/2021	Buy	21,084	$13.06	$275,357.04	35,354

Gabrielle Sulzberger Buying and Selling Activity at Cerevel Therapeutics

Cerevel Therapeutics Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $42.14

$41.70

$42.21

50 Day Range

MA: $41.95

$40.88

$43.27

2 Week Range

Now: $42.14

$19.59

$43.59

Volume

1,282,829 shs

Average Volume

1,523,868 shs

Market Capitalization

$7.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story